Plasma Protein Therapeutics Market (2026 - 2033)

Plasma Protein Therapeutics Market Summary

The global plasma protein therapeutics market was valued at USD 2.1 billion in 2025 and is projected to grow from USD 2.2 billion in 2026 to USD 2.9 billion in 2033, at a CAGR of 4.3% from 2026 to 2033. Asia Pacific dominated the market, accounting for a revenue share of 35.0% in 2025. The growth of plasma protein therapeutics market is driven by increasing use of plasma-derived therapies in immunology, hematology, neurology, and critical care applications, along with rising demand for immunoglobulins, albumin, and coagulation factors. In addition, rising healthcare expenditure, expanding access to advanced biologic therapies, and increasing prevalence of chronic and rare diseases continue to support market expansion.

The growing burden of immune deficiencies, autoimmune disorders, bleeding disorders, and neurological conditions has increased the utilization of plasma-derived therapeutic products across healthcare settings. Plasma proteins play a critical role in replacement therapies and disease management, particularly in patients requiring immunoglobulins, albumin, and coagulation factor therapies. Their established clinical efficacy and expanding therapeutic applications continue to support adoption across both developed and emerging healthcare markets.

Source: Grand View Research, IR Documents, Primary Interviews, Paid Databases

To learn more about this report, Download Free Sample Report

Product availability and supply chain expansion remain important factors influencing market development. For instance, in March 2025, Octapharma announced that NHS patients in the UK had begun receiving medicines manufactured from UK-donated plasma for the first time in nearly 30 years. The plasma-derived medicinal products include immunoglobulins and albumin, which are used to treat immune deficiencies, infections, and other chronic conditions.

Ongoing clinical research is expanding the therapeutic scope of plasma-derived products across multiple disease areas. Immunoglobulins continue to witness increasing utilization in neurological and immunological disorders, while albumin is being evaluated for additional applications, including liver disease, sepsis, and neurodegenerative conditions. Furthermore, advancements in plasma fractionation technologies, manufacturing processes, and product development are supporting the introduction of more specialized plasma-derived therapies, contributing to the long-term growth of the market.

Analyst Perspective

The plasma protein therapeutics market remains strategically important due to the limited availability of alternative treatments for several immune, hematological, and neurological disorders. Demand continues to be shaped by the expanding use of immunoglobulins and albumin across both established and emerging therapeutic applications. Unlike many conventional biologics, market expansion is closely tied to plasma collection capacity and fractionation infrastructure, making supply availability a critical competitive factor. Future growth will depend on improving plasma sourcing efficiency, expanding treatment accessibility, and advancing plasma-derived therapies for broader clinical applications.

Product Insights

The immunoglobulin segment accounted for the largest revenue share of approximately 50.5% in 2025. The segment's dominance is attributed to its extensive use in the treatment of primary immunodeficiency disorders, autoimmune diseases, and neurological conditions. Expanding therapeutic applications and rising diagnostic rates continue to drive demand across healthcare settings. For instance, in June 2025, Takeda announced Takeda received U.S. FDA approval for GAMMAGARD LIQUID ERC, an immunoglobulin therapy formulated for intravenous and subcutaneous administration in individuals with primary immunodeficiency. The approval broadened the company’s immunoglobulin portfolio and expanded available treatment options for patients requiring long-term immune replacement therapy.

The albumin segment is expected to grow at the fastest CAGR during the forecast period, driven by increasing use of albumin in the management of liver diseases, critical care conditions, trauma, burns, and hypoalbuminemia. Rising diagnosis rates of chronic liver disorders and growing utilization of albumin across hospital settings continue to support demand. In addition, strong consumption in Asia, particularly in China, remains a key driver of segment expansion, supported by rising healthcare utilization and demand for plasma-derived therapies.

Application Insights

The PID segment held the largest market share of around 26.5% in 2025. The lifelong requirement for immunoglobulin replacement therapy among patients with impaired immune function. Increasing awareness of primary immunodeficiency disorders, improved diagnostic capabilities, and expanding access to specialized treatment centers have contributed to higher treatment rates across developed and emerging markets. In addition, the growing recognition of PID as an underdiagnosed condition has supported earlier diagnosis and disease management. The established clinical use of immunoglobulin therapies to reduce infection risk and improve patient outcomes continues to support the segment's leading market position.

The other segments are expected to grow at the fastest CAGR during the forecast period. The segment includes neurological disorders, liver diseases, sepsis, trauma, burns, and other critical care applications where plasma-derived therapies play an important therapeutic role. Expanding clinical research evaluating plasma proteins across broader disease areas is contributing to increased utilization beyond traditional indications. Rising use of albumin in critical care and liver disease management, along with growing adoption of immunoglobulins for selected neurological conditions, continues to support demand. Furthermore, ongoing investigation of plasma-derived products across emerging therapeutic applications is expected to broaden their clinical utility and contribute to future segment growth.

Regional Insights

Asia Pacific accounted for the largest market share of approximately 35.0% in 2025 and is expected to grow at the fastest CAGR over the forecast period. China ranks first in the global albumin market, supported by high demand and usage of albumin. In addition, factors such as rising demand for advanced treatment options, developing economies, and rising per capita income are anticipated to create growth opportunities for market players in emerging countries over the forecast period.

To learn more about this report, Download Free Sample Report

Europe Plasma Protein Therapeutics Market Trends

Europe is expected to witness fastest growth during the forecast period. Demand for plasma protein therapeutics is driven by a well-established healthcare system, increasing utilization of immunoglobulin therapies, and a growing elderly population. The region also benefits from strong plasma collection and fractionation capabilities, which support the availability of plasma-derived medicinal products. Furthermore, the rising prevalence of immune-related and neurological disorders, along with continued investments in advanced therapeutic development, is driving sustained market expansion across European countries.

Plasma Protein Therapeutics Company Insights

Major companies operating in the plasma protein therapeutics market are strengthening their positions through plasma collection expansion, product portfolio enhancement, manufacturing capacity investments, and regulatory approvals. Industry participants continue to focus on increasing the availability of immunoglobulins, albumin, and coagulation factors to address growing therapeutic demand across multiple disease indications. Strategic collaborations, acquisitions, and investments in plasma fractionation technologies remain important competitive initiatives across the market.

Plasma Protein Therapeutics Companies:

The following key companies have been profiled for this study on the plasma protein therapeutics market:

• CSL
• Grifols, S.A.
• Takeda
• Octapharma AG
• Biotest AG
• Kedrion S.p.A.
• LFB S.A.
• Japan Blood Products Organization
• ADMA Biologics, Inc.
• SK Plasma Co., Ltd.

Recent Developments

• In August 2025, Accord Plasma B.V., part of Intas Pharmaceuticals, completed the acquisition of Prothya Biosolutions Belgium BV and its affiliated entities. Through this transaction, the company enhanced its footprint in the plasma-derived medicinal products sector while expanding operational and production capabilities within the European market.

• In July 2025, Grifols announced the expansion of its manufacturing facility in Lliçà de Vall, Barcelona, supported by an investment of approximately USD 184 million. The expansion is expected to double the company's plasma fractionation capacity in Europe and increase the production of plasma-derived medicines to address growing patient demand across the region.

Global Plasma Protein Therapeutics Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and analyzes the latest industry trends in each sub-segment from 2021 to 2033. For this study, Grand View Research has segmented the global plasma protein therapeutics market report based on product, application, and region:

• Product Outlook (Revenue, USD Billion, 2021 - 2033)
  • Albumin
  • Immunoglobulin
  • Plasma-derived Factor VIII
  • Others
• Application Outlook (Revenue, USD Billion, 2021 - 2033)
  • Hemophilia
  • Primary Immunodeficiency Disorder (PIDD)
  • Idiopathic Thrombocytopenic Purpura (ITP)
  • Others
• Regional Outlook (Revenue, USD Billion, 2021 - 2033)
  • North America
    • U.S.
    • Canada
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • Thailand
    • South Korea
  • Latin America
    • Brazil
    • Mexico
    • Argentina
  • Middle East and Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait